Zimbabwe has rejected a substantial US healthcare agreement valued at 367 million US dollars (272 million pounds) over five years due to the United States' demand for sensitive information.
This rejection became public following a official document dated December was disclosed, which showed President Emmerson Mnangagwa felt the deal was "unbalanced".
A government spokesperson later explained that the US was seeking biological samples for research and commercial gain but refused to share the benefits from any future vaccines.
"We are forced to start the challenging and unfortunate process of scaling back our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy noted the United States had donated more than $1.9bn as health assistance to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has appealed for continued talks to reach a agreement acceptable to all parties so the nation's vital HIV treatment initiative can proceed.
Broader Background
This rejection follows a similar case in neighbouring Kenya, where a high court halted a related health funding agreement following concerns were raised about the safety of Kenyans' medical information.
Since returning to office recently, US President Donald Trump has slashed overseas assistance and closed the US Agency for International Development (USAID).
The agency had administered assistance for the US government, but Trump stated its expenditure was "inefficient" and his government was pursuing direct bilateral agreements to boost openness and accountability.
According to reports, Sixteen nations in Africa have to date agreed to similar agreements, constituting more than $18.3bn of fresh investment.
Specifics of the Rejected Deal
This assistance for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this cooperation might have yielded significant advantages for the people of Zimbabwe, particularly the 1.2 million currently receiving antiretroviral therapy through US-supported initiatives," the Ambassador said.
However, official spokesman Nick Mangwana maintained the proposed deal was "asymmetrical".
"Zimbabwe was being asked to surrender its biological resources and data over an extended period, with no equivalent assurance of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could be developed from that shared data," Mangwana explained.
"In essence, our nation would supply the basic resources for scientific discovery without any assurance that the resulting innovations would be accessible to our population should a future disease outbreak arise."
Sovereignty and Global Health
Mangwana further noted that the American exit from the global health body and its pursuit of bilateral health agreements were disrupting frameworks previously set up through the global health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing system designed to deal with potential global health emergencies.
"This mechanism is designed to ensure that when a country contributes its information, the benefits – such as vaccines and treatments – are shared equitably, not commercialised exclusively by those with the resources to create them."
These objections over the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We encourage ongoing discussions with our US partners on how future collaboration might be structured in a way that honours the independence and interests of both nations."
Health Experts Reaction
Medical experts stated it recognised the official position, but urged that negotiations must proceed considering much of the nation's Aids initiatives relied on external financing.
"In cases where technical issues arise, including those involving information security or agreement terms, these can often be addressed through detailed discussion and negotiated safeguards," it said.
This impasse highlights the complex tensions between receiving much-needed international aid and protecting local interests in an ever more data-driven world.